Literature DB >> 11829079

Mechanisms of bone remodeling: implications for clinical practice.

Anne M Kenny1, Lawrence G Raisz.   

Abstract

The adult skeleton undergoes continuous remodeling. The remodeling cycle involves the interaction of cells of osteoblastic and osteoclastic lineage and is regulated by both systemic hormones and local factors. In addition to the systemic calcium-regulating hormones, parathyroid hormone, 1,25-dihydroxy vitamin D and calcitonin, sex hormones play an important role. Estrogen has been identified as the major inhibitor of bone resorption in both men and women. Androgen is important not only as a source of estrogen, through the action of aromatase, but also for its direct effect in stimulating bone formation. The effects of sex hormones may be mediated by their ability to alter the secretion of local cytokines, prostaglandins and growth factors. Sex hormone action is also modulated by the level of sex hormone-binding globulin in the circulation. A more precise analysis of these effects has been made possible by the development of new methods of measuring not only bone mineral density, but also relative rates of bone formation and resorption using biochemical markers. These new approaches have allowed us to define more precisely the specific roles of androgens, estrogens and other regulatory hormones in human skeletal physiology and pathophysiology.

Entities:  

Mesh:

Year:  2002        PMID: 11829079

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  7 in total

1.  Androgen prevents hypogonadal bone loss via inhibition of resorption mediated by mature osteoblasts/osteocytes.

Authors:  Kristine M Wiren; Xiao-Wei Zhang; Dawn A Olson; Russell T Turner; Urszula T Iwaniec
Journal:  Bone       Date:  2012-08-14       Impact factor: 4.398

2.  Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis: a model for compartment-specific androgen action in the skeleton.

Authors:  Kristine M Wiren; Anthony A Semirale; Xiao-Wei Zhang; Adrian Woo; Steven M Tommasini; Christopher Price; Mitchell B Schaffler; Karl J Jepsen
Journal:  Bone       Date:  2008-05-16       Impact factor: 4.398

Review 3.  Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects.

Authors:  Marino Muxfeldt Bianchin; Heraldo M Capella; Daniel Loureiro Chaves; Mário Steindel; Edmundo C Grisard; Gerson Gandi Ganev; João Péricles da Silva Júnior; Schaeffer Neto Evaldo; Mônica Aparecida Poffo; Roger Walz; Carlos G Carlotti Júnior; Américo C Sakamoto
Journal:  Cell Mol Neurobiol       Date:  2004-02       Impact factor: 5.046

Review 4.  Bone health and associated metabolic complications in neuromuscular diseases.

Authors:  Nanette C Joyce; Lauren P Hache; Paula R Clemens
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-10-17       Impact factor: 1.784

5.  Effects of modified Shu-Gan-Liang-Xue decoction combined with anastrozole on osteoblastic proliferation and differentiation of MC3T3-E1 cells.

Authors:  Fei Zhou; Shuyan Han; Ning Zhou; Wenxian Zheng; Pingping Li
Journal:  Mol Med Rep       Date:  2014-11-17       Impact factor: 2.952

6.  Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors.

Authors:  Claudia Angela Maria Fulgenzi; Andrea Napolitano; Eliodoro Faiella; Laura Messina; Gennaro Castiello; Flavia Paternostro; Marianna Silletta; Francesco Pantano; Giuseppe Tonini; Daniele Santini; Bruno Vincenzi
Journal:  J Bone Oncol       Date:  2022-03-09       Impact factor: 4.072

7.  Aesculetin Inhibits Osteoclastic Bone Resorption through Blocking Ruffled Border Formation and Lysosomal Trafficking.

Authors:  Woojin Na; Eun-Jung Lee; Min-Kyung Kang; Yun-Ho Kim; Dong Yeon Kim; Hyeongjoo Oh; Soo-Il Kim; Su Yeon Oh; Young-Hee Kang
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.